With all signs pointing to an M&A boom in late 2021 and throughout 2022, our guest will provide valuable insight into current and emerging trends in the biotech investing landscape.

In this episode of The Pharma Letter Podcast, we speak with Lance Minor, principal and national co-leader of the life sciences practice at BDO, a global business intelligence firm.

With the coronavirus pandemic continuing to cast its shadow across the life sciences, we look at how external factors - such as supply chain disruption and clinical trial delays - could help explain a recent slowdown in research spending.

We also discuss the likely impact of record high valuations for drug development startups, including what that might mean for future spending on research and development.

Co-author of BDO’s Summer 2021 Biotech Brief, Lance explains how more cash on hand and increased debt will shape the sector in the coming period.